High content screening in neurodegenerative diseases

Journal of Visualized Experiments

Volumn , Issue 59, 2012, Pages 1-8

  Jain, Shushant ^a   van Kesteren, Ronald E ^b   Heutink, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Automated cell culturing; High content screening; High throughput screening; Issue 59; Medicine; Neurodegeneration; Parkinson's disease

Indexed keywords

EID: 84857026476     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/3452     Document Type: Article

References (38)

1. Geschwind, D.H. & Konopka, G. Neuroscience in the era of functional genomics and systems biology. Nature. 461, 908-15 (2009).
2. Ge, H., Walhout, A.J., & Vidal, M. Integrating 'omic' information: a bridge between genomics and systems biology. Trends. Genet. 19, 551-60 (2003).
3. Zhu, H. & Snyder, M. 'Omic' approaches for unraveling signaling networks. Curr. Opin. Cell. Biol. 14, 173-9 (2002).
4. Jain, S. & Heutink, P. From single genes to gene networks: high-throughput-high-content screening for neurological disease. Neuron. 68, 207-17 (2010).
5. Manolio, T.A., et al. Finding the missing heritability of complex diseases. Nature. 461, 747-53 (2009).
6. Nalls, M.A., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 377, 641-9 (2011).
7. Simon-Sanchez, J., et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur. J. Hum. Genet. 19 (6), 655-61 (2011).
8. Van Regenmortel, M.H. Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological and overcome the limitations of reductionism. EMBO. Rep. 5, 1016-20 (2004).
9. Aherne, G.W., McDonald, E., & Workman, P. Finding the needle in the haystack: why high-throughput screening is good for your health. Breast. Cancer. Res. 4, 148-54 (2002).
10. An, W.F. & Tolliday, N.J. Introduction: cell-based assays for high-throughput screening. Methods. Mol. Biol. 486, 1-12 (2009).
11. Mayr, L.M. & Bojanic, D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 9, 580-8 (2009).
12. Hertzberg, R.P. & Pope, A.J. High-throughput screening: new technology for the 21st century. Curr. Opin. Chem. Biol. 4, 445-51 (2000).
13. Conrad, C. & Gerlich, D.W. Automated microscopy for high-content RNAi screening. J. Cell. Biol. 188, 453-61 (2010).
14. Thomas, N. High-content screening: a decade of evolution. J. Biomol. Screen. 15, 1-9 (2010).
15. Arrasate, M. & Finkbeiner, S. Automated microscope system for determining factors that predict neuronal fate. Proc. Natl. Acad. Sci. U. S. A. 102, 3840-5 (2005).
16. Dragunow, M. High-content analysis in neuroscience. Nat. Rev. Neurosci. 9, 779-88 (2008).
17. Varma, H., Lo, D.C., & Stockwell, B.R. High throughput screening for neurodegeneration and complex disease phenotypes. Comb. Chem. High. Throughput. Screen. 11, 238-48 (2008).
18. Durr, O., et al. Robust hit identification by quality assurance and multivariate data analysis of a high-content, cell-based assay. J. Biomol. Screen. 12, 1042-9 (2007).
19. Miller, J., et al. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J. Neurosci. 30, 10541-50 (2010).
20. Jain, S., Sondervan, D., Rizzu, P., Bochdanovits, Z. Caminada, D., & Heutink, P. The Complete Automation of Cell Culture. Journal of Biomolecular Screening. 16 (8), DOI: 10.1177/1087057111413920 (2011).
21. Bonifati, V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 299, 256-9 (2003).
22. Ricardo, R. & Phelan, K. Trypsinizing and Subculturing Mammalian Cells. J. Vis. Exp. (16), e755, DOI: 10.3791/755 (2008).
23. Kent, L. Culture and Maintenance of Human Embryonic Stem Cells. J. Vis. Exp. (34), e1427, DOI: 10.3791/1427 (2009).
24. Moffat, J., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 124, 1283-98 (2006).
25. Volksgezondheid, M.V. Integrale versie van de Regeling genetisch gemodificeerde organismen en het Besluit genetische gemodificeerde. Organismen., (2004).
26. Anderl, J.L., Redpath, S., & Ball, A.J. A Neuronal and Astrocyte Co-Culture Assay for High Content Analysis of Neurotoxicity. J. Vis. Exp. (27), e1173, DOI: 10.3791/1173 (2009).
27. Wiles, A.M., Ravi, D., Bhavani, S., & Bishop, A.J. An analysis of normalization methods for Drosophila RNAi genomic screens and development of a robust validation scheme. J. Biomol. Screen. 13, 777-84 (2008).
28. Canet-Aviles, R.M., et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U. S. A. 101, 9103-8 (2004).
29. Blackinton, J., et al. Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J. Biol. Chem. 284, 6476-85 (2009).
30. Gupta, P.B., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 138, 645-59 (2009).
31. Luo, J., et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 137, 835-48 (2009).
32. Mouchet, E.H. & Simpson, P.B. High-content assays in oncology drug discovery: opportunities and challenges. IDrugs. 11, 422-7 (2008).
33. Vogt, A., et al. Automated image-based phenotypic analysis in zebrafish embryos. Dev. Dyn. 238, 656-63 (2009).
34. Pardo-Martin, C., et al. High-throughput in vivo vertebrate screening. Nat. Methods. 7, 634-6 (2010).
35. Vogt, A., Codore, H., Day, B.W., Hukriede, N.A., & Tsang, M. Development of automated imaging and analysis for zebrafish chemical screens. J. Vis. Exp. (40), e1900, DOI: 10.3791/1900 (2010).
36. Ross, P.J. & Ellis, J. Modeling complex neuropsychiatric disease with induced pluripotent stem cells. F1000. Biol. Rep. 2, 84 (2010).
37. Ebert, A.D. & Svendsen, C.N. Human stem cells and drug screening: opportunities and challenges. Nat. Rev. Drug. Discov. 9, 367-72 (2010).
38. An, W.F. & Tolliday, N. Cell-based assays for high-throughput screening. Mol. Biotechnol. 45, 180-6 (2010).